Application of gene transfer technologies to transplantation

Therapeutic Drug Monitoring

Volumn 26, Issue 3, 2004, Pages 248-250

  Anegon, Ignacio ^a   Guillonneau, Carole ^a   Hill, Marcelo ^a   Chauveau, Christine ^a  

^a INSERM   (France)

Author keywords

Gene transfer technology; Transplantation

Indexed keywords

ADENOVIRUS VECTOR; CD40 ANTIGEN; CD59 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECAY ACCELERATING FACTOR; HEME OXYGENASE 1; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; LENTIVIRUS VECTOR; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN; MEMBRANE COFACTOR PROTEIN; NAKED DNA; PARVOVIRUS VECTOR; PROTEIN BCL 2; RETROVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA;

B LYMPHOCYTE; DNA VECTOR; GENE TRANSFER; GERM LINE; GRAFT VERSUS HOST REACTION; NONHUMAN; OPPORTUNISTIC INFECTION; PARACRINE SIGNALING; PRIORITY JOURNAL; SHORT SURVEY; SOMATIC CELL; T LYMPHOCYTE; TRANSGENIC ANIMAL; TRANSPLANTATION;

GENE TRANSFER TECHNIQUES; GRAFT REJECTION; HUMANS; TRANSPLANTATION;

EID: 2542548090     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200406000-00004     Document Type: Short Survey

References (28)

1. Guillot C, Le Mauff B, Cuturi MC, et al. Gene therapy in transplantation in the year 2000: moving towards clinical applications? Gene Ther. 2000;7:14-19.
2. Wood K, Prior T. Gene therapy in transplantation. Curr Opin Mol Ther. 2001;3:390-398.
3. Mathieu P, Chauveau C, Bouchet D, et al. Genetic engineering in allotransplantation of vascularized organs. Curr Gene Ther. 2002;2:9-21.
4. Davis ME. Non-viral gene delivery systems. Curr Opin Biotechnol. 2002;13:128-131.
5. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nature Rev Genet. 2003;4:346-358.
6. Guillot C, Mathieu P, Coathalem H, et al. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. J Immunol. 2000;164:5258-5268.
7. Guillot C, Guillonneau C, Mathieu P, et al. Prolonged blockade of CD40-CD40L interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness but does not prevent chronic rejection. J Immunol. 2002;168:1600-1699.
8. Min WP, Gorczynski R, Huang XY, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol. 2000;164:161-167.
9. Madsen JC, Superina RA, Wood KJ, et al. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature. 1988;332:161-164.
10. Qin L, Chavin KD, Ding Y, et al. Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol. 1996;156:2316-2323.
11. David A, Chetritt J, Heslan J-M, et al. Prolongation of rat cardiac allograft induced by adenovirus-mediated gene transfer of IL-10. Gene Ther. 2000;7:505-510.
12. Josien R, Douillard P, Guillot C, et al. A critical role for transforming growth factor-β (TGF-β) in donor transfusion-induced allograft tolerance. J Clin Invest. 1998;102:1920-1926.
13. Barrou B, Bertry-Coussot L, Morin S, et al. Prolonged islet allograft survival by adenovirus-mediated transfer of sICAM-1/Ig immunoadhesin gene. Hum Gene Ther. 2002;13:1441-1450.
14. DeBruyne LA, Li K, Bishop DK, et al. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity. Gene Ther. 2000;7:575-582.
15. Thomas-Valin V, Bellier B, Cohen J, et al. Prolonged allograft survival through conditional and specific ablation of alloreactive T cells expressing a suicide gene. Transplantation. 2000;69:2154-2161.
16. Charreau B, Tesson L, David A, et al. Adenovirus-mediated expression of human CD59 on xenogeneic endothelial cells: protection against human complement-mediated lysis and induction of cellular activation by adenoviral transduction. Xenotransplantation. 1997;4:212-221.
17. Contreras J, Bilbao G, Smyth C, et al. Cytoprotection of pancreatic islets before and soon after transplantation by gene transfer of the anti-apoptotic Bcl-2 gene. Transplantation. 2001;71:1015-1023.
18. Grey S, Arvelo M, Hasenkamp W, et al. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. J Exp Med. 1999;190:1135-1146.
19. Engelhardt J. Redox-mediated gene therapies for environmental injury: approaches and concepts. Antioxid Redox Signal. 1999;1:5-27.
20. Amersi F, Buelow R, Kato H, et al. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury [see comments]. J Clin Invest. 1999;104:1631-1639.
21. Chauveau C, Bouchet D, Roussel J-C, et al. Gene transfer of heme-oxygenase 1 and carbon monoxyde delivery inhibit chronic rejection. Am J Transplant. 2002;2:581-592.
22. Green DR, Ware CF. Fas-ligand: privilege and peril. Proc Natl Acad Sci USA. 1997;94:5986-5990.
23. Bouchet D, Tesson L, Ménoret S, et al. Differential sensitivity of endothelial cells of various species to apoptosis induced by gene transfer of Fas ligand: role of FLIP levels. Mol Med. 2002;8:612-623.
24. Braudeau C, Bouchet D, Tesson L, et al. Induction of long-term cardiac allograft survival by heme-oxygenase-1 gene transfer. Gene Ther. 2004;11:701-710.
25. Cohen JL, Boyer O, Klatzmann D. Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation? Immunol Today. 1999;20:172-176.
26. Christ M. Preclinical evaluation of gene transfer products: safety and immunological aspects. Toxicology. 2002;174:13-19.
27. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286:2244-2245.
28. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-256.